There was a significant interaction between treatment and disease activity status with respect to radiographic progression (P<.001 for all outcome measures). In addition, treatment with ADA for 24 wks compared with PBO resulted in significantly lower mean mTSS even in pts with moderate or high disease activity (TA-DAPSA or TA-PASDAS) or not achieving MDA (Table) . Radiographic progression showed a weak, but significant correlation with disease activity status in pts treated with PBO (r p ≥0.3, P<.001 for TA-DAS [CRP] , TA-DAPSA, and TA-PASDAS; r φ = -0.14 [95% CI:-0.20 to -0.09 for MDA), but not ADA.
Conclusions:
The results showed that the relationship between disease activity as determined by various outcome measures differed between ADA and PBO treated pts. ADA provided inhibition of radiographic progression which was somewhat larger and independent of the control of clinical disease activity. This supports the disconnect phenomenon in PsA following ADA treatment.
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